These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 35892151)

  • 21. Genetic predisposition to ductal carcinoma in situ of the breast.
    Petridis C; Brook MN; Shah V; Kohut K; Gorman P; Caneppele M; Levi D; Papouli E; Orr N; Cox A; Cross SS; Dos-Santos-Silva I; Peto J; Swerdlow A; Schoemaker MJ; Bolla MK; Wang Q; Dennis J; Michailidou K; Benitez J; González-Neira A; Tessier DC; Vincent D; Li J; Figueroa J; Kristensen V; Borresen-Dale AL; Soucy P; Simard J; Milne RL; Giles GG; Margolin S; Lindblom A; Brüning T; Brauch H; Southey MC; Hopper JL; Dörk T; Bogdanova NV; Kabisch M; Hamann U; Schmutzler RK; Meindl A; Brenner H; Arndt V; Winqvist R; Pylkäs K; Fasching PA; Beckmann MW; Lubinski J; Jakubowska A; Mulligan AM; Andrulis IL; Tollenaar RA; Devilee P; Le Marchand L; Haiman CA; Mannermaa A; Kosma VM; Radice P; Peterlongo P; Marme F; Burwinkel B; van Deurzen CH; Hollestelle A; Miller N; Kerin MJ; Lambrechts D; Floris G; Wesseling J; Flyger H; Bojesen SE; Yao S; Ambrosone CB; Chenevix-Trench G; Truong T; Guénel P; Rudolph A; Chang-Claude J; Nevanlinna H; Blomqvist C; Czene K; Brand JS; Olson JE; Couch FJ; Dunning AM; Hall P; Easton DF; Pharoah PD; Pinder SE; Schmidt MK; Tomlinson I; Roylance R; García-Closas M; Sawyer EJ
    Breast Cancer Res; 2016 Feb; 18(1):22. PubMed ID: 26884359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast].
    Yang M; Xu SP; Ao QL
    Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):257-61. PubMed ID: 23928534
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DCIS with Microinvasion: Is It In Situ or Invasive Disease?
    Champion CD; Ren Y; Thomas SM; Fayanju OM; Rosenberger LH; Greenup RA; Menendez CS; Hwang ES; Plichta JK
    Ann Surg Oncol; 2019 Oct; 26(10):3124-3132. PubMed ID: 31342393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Whole-Exome Sequencing Analysis of the Progression from Non-Low-Grade Ductal Carcinoma
    Pareja F; Brown DN; Lee JY; Da Cruz Paula A; Selenica P; Bi R; Geyer FC; Gazzo A; da Silva EM; Vahdatinia M; Stylianou AA; Ferrando L; Wen HY; Hicks JB; Weigelt B; Reis-Filho JS
    Clin Cancer Res; 2020 Jul; 26(14):3682-3693. PubMed ID: 32220886
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
    Steinman S; Wang J; Bourne P; Yang Q; Tang P
    Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytoplasmic FOXP1 expression is correlated with ER and calpain II expression and predicts a poor outcome in breast cancer.
    Yu BH; Li BZ; Zhou XY; Shi DR; Yang WT
    Diagn Pathol; 2018 May; 13(1):36. PubMed ID: 29848352
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic performance of minimum apparent diffusion coefficient value in differentiating the invasive breast cancer and ductal carcinoma
    Zhao S; Shao G; Chen P; Li L; Yang Y; Zhao X; Guo W
    J Cancer Res Ther; 2019; 15(4):871-875. PubMed ID: 31436245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genomic differences between pure ductal carcinoma in situ and synchronous ductal carcinoma in situ with invasive breast cancer.
    Kim SY; Jung SH; Kim MS; Baek IP; Lee SH; Kim TM; Chung YJ; Lee SH
    Oncotarget; 2015 Apr; 6(10):7597-607. PubMed ID: 25831047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Single-cell transcriptome analysis reveals immune microenvironment changes and insights into the transition from DCIS to IDC with associated prognostic genes.
    Sun Y; Pan Z; Wang Z; Wang H; Wei L; Cui F; Zou Q; Zhang Z
    J Transl Med; 2024 Oct; 22(1):894. PubMed ID: 39363164
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overexpression of TPL2 may be a predictor of good prognosis in patients with breast invasive ductal carcinoma.
    Yu Q; Wan D; Fu R; Li F; Zhang Y
    Sci Rep; 2023 Oct; 13(1):17346. PubMed ID: 37833434
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation of the ultrasound imaging of breast cancer and the expression of molecular biological indexes.
    Xu J; Li F; Chang F
    Pak J Pharm Sci; 2017 Jul; 30(4(Suppl.)):1425-1430. PubMed ID: 29043992
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recognizing breast ductal carcinoma in situ on fine-needle aspiration: a diagnostic dilemma.
    Guo HQ; Zhang ZH; Zhao H; Zhao LL; Pan QJ
    Diagn Cytopathol; 2013 Aug; 41(8):710-5. PubMed ID: 23729369
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bax protein expression in DCIS of the breast in relation to invasive ductal carcinoma and other molecular markers.
    Rehman S; Crow J; Revell PA
    Pathol Oncol Res; 2000; 6(4):256-63. PubMed ID: 11173657
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer.
    Allred DC; Clark GM; Molina R; Tandon AK; Schnitt SJ; Gilchrist KW; Osborne CK; Tormey DC; McGuire WL
    Hum Pathol; 1992 Sep; 23(9):974-9. PubMed ID: 1355464
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Different distribution of breast cancer subtypes in breast ductal carcinoma in situ (DCIS), DCIS with microinvasion, and DCIS with invasion component.
    Yu KD; Wu LM; Liu GY; Wu J; Di GH; Shen ZZ; Shao ZM
    Ann Surg Oncol; 2011 May; 18(5):1342-8. PubMed ID: 21042943
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessing the correlation between FDG PET findings of IDC breast carcinoma and histopathology of coexisting ductal carcinoma in-situ.
    Sarikaya I; Sarikaya A; Albatineh AN; Tastekin E; Sezer YA
    Nucl Med Rev Cent East Eur; 2022; 25(1):6-11. PubMed ID: 35137931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the association of mammographic density and clinical factors with ductal carcinoma in situ versus invasive ductal breast cancer in Korean women.
    Ko H; Shin J; Lee JE; Nam SJ; Nguyen TL; Hopper JL; Song YM
    BMC Cancer; 2017 Dec; 17(1):821. PubMed ID: 29207971
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40).
    von Minckwitz G; Darb-Esfahani S; Loibl S; Huober J; Tesch H; Solbach C; Holms F; Eidtmann H; Dietrich K; Just M; Clemens MR; Hanusch C; Schrader I; Henschen S; Hoffmann G; Tiemann K; Diebold K; Untch M; Denkert C
    Breast Cancer Res Treat; 2012 Apr; 132(3):863-70. PubMed ID: 21667238
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.
    Elsarraj HS; Hong Y; Valdez KE; Michaels W; Hook M; Smith WP; Chien J; Herschkowitz JI; Troester MA; Beck M; Inciardi M; Gatewood J; May L; Cusick T; McGinness M; Ricci L; Fan F; Tawfik O; Marks JR; Knapp JR; Yeh HW; Thomas P; Carrasco DR; Fields TA; Godwin AK; Behbod F
    Breast Cancer Res; 2015 Sep; 17():128. PubMed ID: 26384318
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
    Park K; Han S; Kim HJ; Kim J; Shin E
    Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.